Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
Open accessThe DOI matches its Crossref record; 236 of the 237 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
The protein p53, known as the “Guardian of the Genome”, plays an important role in maintaining DNA integrity, providing protection against cancer-promoting mutations. Dysfunction of p53 is observed in almost every cancer, with 50% of cases bearing loss-of-function mutations/deletions in the TP53 gene. In the remaining 50% of cases the overexpression of HDM2 (mouse double minute 2, human homolog) protein, which is a natural inhibitor of p53, is the most common way of keeping p53 inactive. Disruption of HDM2-p53 interaction with the use of HDM2 antagonists leads to the release of p53 and expression of its target genes, engaged in the induction of cell cycle arrest, DNA repair, senescence, and apoptosis. The induction of apoptosis, however, is restricted to only a handful of p53wt cells, and, generally, cancer cells treated with HDM2 antagonists are not efficiently eliminated. For this reason, HDM2 antagonists were tested in combinations with multiple other therapeutics in a search for synergy that would enhance the cancer eradication. This manuscript aims at reviewing the recent progress in developing strategies of combined cancer treatment with the use of HDM2 antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“According to these three clear binding sites, a variety of structural types of MDM2 inhibitors have been reported, among which nine have entered clinical trials (RG7112, RG7388/RO6839921, MK-8242, AMG232, SAR405838, DS-3032b, HDM201, NVP-CGM097 and APG-115) (Fig. 3), with a variety of scaffold types [15–18].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, MDM2 inhibitors sensitize cells to a range of other therapies, including radiation, thus enhancing response to standard-of-care therapy for GBM (6).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MDM2 inhibitors can enhance response to both radiation therapy (RT) and temozolomide,7-9 the standard of care for GBM.”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 1×
“Direct DNA damage is caused by the introduction of DNA strand breaks, while indirect is mediated by the production of reactive oxygen species (ROS), which in turn lead to many DNA modifications like formation of abasic sites, DNA adducts, single-strand breaks (SSBs) and double-strand breaks (DSBs), DNA-protein crossli…”
BackgroundCisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537 · cited 2×
“This forms monofunctional adducts or inter-strand, intra-strand, or DNA-protein crosslinks [127].”
BackgroundThe resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717 · cited 1×
“Platinum complexes are molecules that form covalent links between DNA nucleobases, bridged by the platinum atom-containing moieties (a mechanism similar to that of alkylating agents) [126].”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“One of the earliest HDM2 antagonists, discovered by Hoffman-La Roche (Basel, Switzerland) in the early 21st century, are called the nutlins and are built around the cis-imidazoline core [113].”
BackgroundTumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063 · cited 1×
“This version of p53 results in the induction of apoptosis at least partially by the activation of a positive p53-PTEN (phosphatase and tensin homolog deleted on chromosome ten)-Akt-HDM2 loop [23] and induction of the expression of pro-apoptotic Bax protein [24].”
BackgroundDu, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000) · Cell · doi:10.1016/s0092-8674(00)00008-8 · Cited by 3,513
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 2×
“ABT-737 is a BH3 inhibitor of BCL-2, BCL-XL, and BCL-W proteins [151,152].”
BackgroundABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“Many studies indicate that ionizing radiation and chemotherapy work better on wild-type p53 tumors [223].”
BackgroundIdentification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Cancer and Radiation Therapy: Current Advances and Future Directions
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3635 · Cited by 2,880 · cited 1×
“Many patients during the cancer treatment receive ionizing radiation, that is either applied alone or in combination with anti-cancer drugs [132].”
BackgroundDNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743 · cited 1×
“Drugs which target topoisomerases are commonly used to treat cancer [125,130].”
BackgroundNasir, O. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000350152 · Cited by 2,331
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284 · cited 1×
“This pathway is responsible for many critical functions of the cell response to extracellular stimuli, such as cytokines, growth factors or mitogen binding to their receptors localized in the cell membrane [182,183].”
BackgroundStructure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · cited 1×
“In the first mode, the activation of p53 results in the induction of the expression of proteins engaged in cell cycle arrest, such as p21 [17], and the proteins that assure negative feedback loops required for the generation of p53 activation pulses, such as HDM2 and Wip-1 (wild-type p53-induced phosphatase 1) [18,19].”
BackgroundInduction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793 · cited 1×
“rhTRAIL induces selective apoptosis in cancer cells and leaves the normal cells unharmed [170,171].”
BackgroundDNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666 · cited 1×
“These compounds either lead to the inhibition of nucleotide biosynthesis or are incorporated into DNA molecules, leading to impaired DNA processing and mutations [125,129].”
BackgroundTargeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485 · cited 2×
“Among them are transcription and translation, metabolism, angiogenesis, cell cycle and apoptosis [188,189].”
BackgroundThe Bcl-2 family: roles in cell survival and oncogenesis
Cory, S., Huang, D. C. S., & Adams, J. M. (2003) · Oncogene · doi:10.1038/sj.onc.1207102 · Cited by 1,463
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 7×
“Tyrosi e kinase rec pt s are responsible for initiation, transmission, and regulatio of m ny cellular pathways connected to cell proliferati n and survival, such as JAK/STAT, PI3K/Akt/mTOR, and Ras/Raf/MEK/MAPK [177,178].”
BackgroundInfluentialvan Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,240
The coordinate regulation of the p53 and mTOR pathways in cells
Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235 · cited 1×
“Among them are transcription and translation, metabolism, angiogenesis, cell cycle and apoptosis [188,189].”
BackgroundThe Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222 · cited 3×
“Moreover, even though oridonin did not increase the level of p53, HDM2, and Puma in the combined strategy nutlin-3 completely abolished the viability of cancer cells.”
BackgroundTargeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Regulation of PTEN Transcription by p53
Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., & Mak, T. W. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00323-9 · Cited by 912 · cited 1×
“This version of p53 results in the induction of apoptosis at least partially by the activation of a positive p53-PTEN (phosphatase and tensin homolog deleted on chromosome ten)-Akt-HDM2 loop [23] and induction of the expression of pro-apoptotic Bax protein [24].”
BackgroundApoptosis and apoptotic body: disease message and therapeutic target potentials
Xu, X., Lai, Y., & Hua, Z.-C. (2019) · Bioscience Reports · doi:10.1042/bsr20180992 · Cited by 909
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
Eckelman, B. P., Salvesen, G. S., & Scott, F. L. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400795 · Cited by 813 · cited 1×
“So far, several human IAPs have been identified and one of the representatives is known as the protein XIAP (X-linked inhibitor of apoptosis protein) [158].”
BackgroundBortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795 · cited 1×
“Bortezomib (Velcade®) was the first proteasome inhibitor designed and approved for cancer treatment, more specifically for multiple myeloma patients [212].”
BackgroundDrugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719 · cited 1×
“In such cells, the administration of HDM2 antagonists results in forced dissociation of HDM2-p53 complexes, releasing p53 from HDM2 inhibition [2].”
BackgroundChaudhary, P. M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., & Hood, L. (1997) · Immunity · doi:10.1016/s1074-7613(00)80400-8 · Cited by 711
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · cited 1×
“First, it soon became clear that HDM2 antagonists induce apoptosis only in a limited subset of p53wt cells [4,5].”
BackgroundDing, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661 · cited 1×
“While deactivation of p53 is a virtually obligatory step in cancer development [1], it is estimated that around 50% of cancers contain non-mutated (wild type) TP53 genes, which encode a functional p53 protein.”
BackgroundShangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · cited 4×
“MI-319 in combination with cisplatin i r . i t it - i t t r s t t s stai a age response.”
BackgroundInfluentialCell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
Engeland, K. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.172 · Cited by 656 · cited 1×
“Moreover, DREAM complex controls genes responsible for DNA repair, telomere maintenance and chromosomal instability [20].”
BackgroundTyrosine kinase – Role and significance in Cancer
Paul, M. K., & Mukhopadhyay, A. K. (2004) · International Journal of Medical Sciences · doi:10.7150/ijms.1.101 · Cited by 624 · cited 2×
“Tyrosine kinase’s functions are tightly controlled, but due to mutations in cancer cells frequently their constant activation occurs, providing an unrestrained flow of survival signaling [179].”
BackgroundDiscovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · cited 2×
“Further research by Roche yielded the second generation compound RG7388 (idasanutlin), which is built on the pyrrolidine core [115].”
BackgroundProteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Orlowski, R. Z., & Kuhn, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2218 · Cited by 578 · cited 1×
“Therefore, inhibition of proteasome activity is a promising anti-cancer strategy (briefly reviewed in [210,211]).”
BackgroundDeath receptor signal transducers: nodes of coordination in immune signaling networks
Wilson, N. S., Dixit, V., & Ashkenazi, A. (2009) · Nature Immunology · doi:10.1038/ni.1714 · Cited by 559
Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism
Froelich-Ammon, S. J., & Osheroff, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21429 · Cited by 505 · cited 1×
“Topoisomerase inhibitors do not block the catalytic function of the enzyme, but they “poison” them by weakening the enzyme ability to religate DNA and/or by increasing the DNA cleavage [131].”
BackgroundZhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · cited 1×
“Several promising compounds are currently being tested in cancer-related clinical trials [30,110].”
BackgroundAn overview of targeted cancer therapy
Padma, V. V. (2015) · BioMedicine · doi:10.7603/s40681-015-0019-4 · Cited by 459
Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1991 · Cited by 446
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
Recurrent Initiation: A Mechanism for Triggering p53 Pulses in Response to DNA Damage
Batchelor, E., Mock, C. S., Bhan, I., Loewer, A., & Lahav, G. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.016 · Cited by 422 · cited 1×
“In the first mode, the activation of p53 results in the induction of the expression of proteins engaged in cell cycle arrest, such as p21 [17], and the proteins that assure negative feedback loops required for the generation of p53 activation pulses, such as HDM2 and Wip-1 (wild-type p53-induced phosphatase 1) [18,19].”
BackgroundAshkenazi, A., Holland, P., & Eckhardt, S. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7198 · Cited by 421
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
Schneider, C., Sepp-Lorenzino, L., Nimmesgern, E., Ouerfelli, O., Danishefsky, S., Rosen, N., & Hartl, F. U. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14536 · Cited by 405 · cited 1×
“HSPs have an impact on protein degradation in proteasome [225].”
BackgroundDiscovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395 · cited 1×
“Following the initial discovery of nulin-3a in 2004, the more potent representative of this family, RG7112, was developed [114].”
BackgroundCombine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394 · cited 1×
“Despite the wide range of anticancer drugs for targeted therapy and many successes in the preclinical research, a great percentage of therapeutics does not provide satisfactory therapeutic outcome when delivered to the patients as single agents [176].”
BackgroundMonoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 392
Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
Chang, B.-D., Xuan, Y., Broude, E. V., Zhu, H., Schott, B., Fang, J., & Roninson, I. B. (1999) · Oncogene · doi:10.1038/sj.onc.1203078 · Cited by 386 · cited 1×
“In the first mode, the activation of p53 results in the induction of the expression of proteins engaged in cell cycle arrest, such as p21 [17], and the proteins that assure negative feedback loops required for the generation of p53 activation pulses, such as HDM2 and Wip-1 (wild-type p53-induced phosphatase 1) [18,19].”
BackgroundTwo-phase dynamics of p53 in the DNA damage response
Zhang, X.-P., Liu, F., & Wang, W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100600108 · Cited by 333 · cited 1×
“Since the transition from p53ARRESTER to p53KILLER requires the accumulation of HIPK2 kinase (homeodomain-interacting protein kinase 2) in response to severe DNA damage [25] and normally occurs after several cycles of the induction of p53ARRESTER protein [22,26,27], it is not easily achieved by a rough p53 release evo…”
BackgroundWang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328 · cited 1×
“Further optimization of spiro-oxindoles led to the discovery of second-generation compounds with reversed stereochemistry and increased affinity [119].”
BackgroundHeat shock proteins: A review of the molecular chaperones
Whitley, D., Goldberg, S. P., & Jordan, W. D. (1999) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(99)70329-0 · Cited by 327 · cited 1×
“Heat shock proteins (HSPs) are responsible for the proper folding of synthesized proteins or refolding under denaturating conditions [224].”
BackgroundMolina, J. R., & Adjei, A. A. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31506-9 · Cited by 324 · cited 1×
“This pathway is responsible for many critical functions of the cell response to extracellular stimuli, such as cytokines, growth factors or mitogen binding to their receptors localized in the cell membrane [182,183].”
BackgroundMechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K., Price, S., Heald, R., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 319 · cited 2×
“A phase 1b/2 clinical study with venetoclax in combination with idasanutlin or cobimetinib (the MEK inhibitor [150]) for the treatment of AML patients is currently running (NCT02670044).”
BackgroundDifferential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 305 · cited 1×
“TRAIL ligand has an affinity to five receptors, among which DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are able to transmit the apoptotic signal [161,163].”
BackgroundOnto better TRAILs for cancer treatment
de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martinez-Lostao, L. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.174 · Cited by 304
Protein kinase C and cancer: what we know and what we do not
Garg, R., Benedetti, L. G., Abera, M. B., Wang, H., Abba, M., & Kazanietz, M. G. (2014) · Oncogene · doi:10.1038/onc.2013.524 · Cited by 303 · cited 1×
“Overexpression of PKCs is often observed in cancer [194,197].”
BackgroundLabi, V, & Erlacher, M. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.20 · Cited by 295
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290 · cited 2×
“(Thousand Oaks, California, USA) as a result of rational design and optimization steps of the initial lead structure [76].”
BackgroundABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 281
Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Isakov, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 270 · cited 1×
“Different isoenzymes of PKC affect many cell functions, such as proliferation, migration, adhesion, survival and malignant transformation, and are crucial players in carcinogenesis and maintenance of malignant phenotype of cancer cells [194,196].”
BackgroundA threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.
Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261 · cited 1×
“Additionally, the forced release of p53 by HDM2 antagonists seem to be devoid of the proper cellular context and other mechanistic features, that is required for enabling proapoptotic functioning of p53 [28].”
BackgroundProtein kinase C (PKC) family in cancer progression
Koivunen, J., Aaltonen, V., & Peltonen, J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.03.033 · Cited by 261 · cited 3×
“Different isoenzymes of PKC affect many cell functions, such as proliferation, migration, adhesion, survival and malignant transformation, and are crucial players in carcinogenesis and maintenance of malignant phenotype of cancer cells [194,196].”
BackgroundTisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256 · cited 3×
“Several promising compounds are currently being tested in cancer-related clinical trials [30,110].”
BackgroundCell fate decision mediated by p53 pulses
Zhang, X.-P., Liu, F., Cheng, Z., & Wang, W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813088106 · Cited by 253 · cited 1×
“Since the transition from p53ARRESTER to p53KILLER requires the accumulation of HIPK2 kinase (homeodomain-interacting protein kinase 2) in response to severe DNA damage [25] and normally occurs after several cycles of the induction of p53ARRESTER protein [22,26,27], it is not easily achieved by a rough p53 release evo…”
BackgroundFollowing a TRAIL: Update on a ligand and its five receptors
KIMBERLEY, F. C., & SCREATON, G. R. (2004) · Cell Research · doi:10.1038/sj.cr.7290236 · Cited by 250 · cited 1×
“TRAIL ligand has an affinity to five receptors, among which DR4 (TRAIL-R1) and DR5 (TRAIL-R2) are able to transmit the apoptotic signal [161,163].”
BackgroundThe mdm-2 gene is induced in response to UV light in a p53-dependent manner.
Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D., & Levine, A. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11623 · Cited by 247 · cited 1×
“Thus, IR therapies were combined with HDM2 antagonists in an attempt to increase the activity of p53 protein [136].”
Lane, D. P., Cheok, C. F., & Lain, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 246
Kojima, K., Konopleva, M., McQueen, T., O'Brien, S., Plunkett, W., & Andreeff, M. (2006) · Blood · doi:10.1182/blood-2005-12-5148 · Cited by 245 · cited 1×
“As an example of pyrimidine nucleoside analog, fludarabine (2-fluoro-ara-AMP) has synergic effect with nutlin-3a in chronic lymphocytic leukemia (CLL) by increasing p53 levels, inducing Bax conformational changes and apoptosis in p53wt cells [48].”
BackgroundColl-Mulet, L., Iglesias-Serret, D., Santidrián, A. F., Cosialls, A. M., de Frias, M., Castaño, E., Campàs, C., Barragán, M., de Sevilla, A. F., Domingo, A., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3273 · Cited by 234 · cited 2×
“nutlin-3a DLBCL, CLL, PDAC, liposarcoma, RMS and osteosarcoma DLBCL xenograft mouse models [33,42,45,46]”
BackgroundASTOLFI, L., GHISELLI, S., GUARAN, V., CHICCA, M., SIMONI, E., OLIVETTO, E., LELLI, G., & MARTINI, A. (2013) · Oncology Reports · doi:10.3892/or.2013.2279 · Cited by 234 · cited 1×
“Successors of cisplatin, carboplatin and oxaliplatin, were introduced to overcome side effects and resistance to cisplatin [128].”
BackgroundCyclin dependent kinase (CDK) inhibitors as anticancer drugs
Sánchez-Martínez, C., Gelbert, L. M., Lallena, M. J., & de Dios, A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.100 · Cited by 230 · cited 2×
“For this reason, inhibitors of cyclin-dependent kinases (CDKs) became a very important group of anti-cancer drugs [192].”
BackgroundRoscovitine in cancer and other diseases.
Cicenas, J., Kalyan, K. P., Sorokinas, A., Stankunas, E., Levy, J., Meskinyte, I., Stankevičius, V., Kaupinis, A., & Valius, M. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.03.61 · Cited by 219 · cited 1×
“with strong activity towards CDK1, CDK2, CDK5, and CDK7, and weak towards CDK4 and CDK6, showed a considerable synergy with nutlin-3a [90,193].”
BackgroundInhibitors of histone deacetylase as antitumor agents: A critical review
Manal, M., Chandrasekar, M. J. N., Gomathi Priya, J., & Nanjan, M. J. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.05.005 · Cited by 216 · cited 1×
“In this therapy, histone deacetylases (HDAC) inhibitors play a major role, with several potent compounds being tested in clinical trials [213].”
BackgroundSwift, L., & Golsteyn, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033403 · Cited by 213 · cited 6×
“Direct DNA damage is caused by the introduction of DNA strand breaks, while indirect is mediated by the production of reactive oxygen species (ROS), which in turn lead to many DNA modifications like formation of abasic sites, DNA adducts, single-strand breaks (SSBs) and double-strand breaks (DSBs), DNA-protein crossli…”
BackgroundInfluentialTargeting the PI3K-AKT-mTOR signaling network in cancer
Khan, K. H., Yap, T. A., Yan, L., & Cunningham, D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.013.10057 · Cited by 213
Aguilar, A., Lu, J., Liu, L., Du, D., Bernard, D., McEachern, D., Przybranowski, S., Li, X., Luo, R., Wen, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01665 · Cited by 211
Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203 · cited 18×
“Pr o- Su rv iv al Si gn al in g Pa th w ay s Ta rg et in g R as /R af /M EK /M A PK In hi bi to rs pimasertib SAR405838 - - different tumor types, Phase 1 NCT01985191[81] trametinib AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels AML, Phase 1b melanoma, Phase 1 [78,79] NCT02016729 NCT…”
BackgroundInfluentialGolemovic, M., Verstovsek, S., Giles, F., Cortes, J., Manshouri, T., Manley, P. W., Mestan, J., Dugan, M., Alland, L., Griffin, J. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2601 · Cited by 203
A tale of two antibodies: obinutuzumab versus rituximab
Freeman, C. L., & Sehn, L. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15232 · Cited by 201
An Overview on Radiotherapy: From Its History to Its Current Applications in Dermatology
Gianfaldoni, S., Gianfaldoni, R., Wollina, U., Lotti, J., Tchernev, G., & Lotti, T. (2017) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2017.122 · Cited by 201 · cited 1×
“The radiation has a direct or indirect impact on DNA damage [133].”
BackgroundTransient Activation of p53 in G2 Phase Is Sufficient to Induce Senescence
Krenning, L., Feringa, F. M., Shaltiel, I. A., van den Berg, J., & Medema, R. H. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.007 · Cited by 193 · cited 1×
“Moreover, it was proposed that it is the pulse of p53 activation in the G2 phase of the cell cycle which result in irreversible senescence of DNA-damaged cell, while HDM2 antagonists arrest the cells predominantly in the G1 phase, where the cells remain the potency of re-entering mitosis [29].”
BackgroundMichaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190
van der Sloot, A. M., Tur, V., Szegezdi, E., Mullally, M. M., Cool, R. H., Samali, A., Serrano, L., & Quax, W. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510187103 · Cited by 169
Managing the adverse effects of radiation therapy.
Berkey, F. J. (2010) · PubMed · Cited by 166
Puca, R., Nardinocchi, L., Givol, D., & D’Orazi, G. (2010) · Oncogene · doi:10.1038/onc.2010.183 · Cited by 153 · cited 1×
“Since the transition from p53ARRESTER to p53KILLER requires the accumulation of HIPK2 kinase (homeodomain-interacting protein kinase 2) in response to severe DNA damage [25] and normally occurs after several cycles of the induction of p53ARRESTER protein [22,26,27], it is not easily achieved by a rough p53 release evo…”
BackgroundCanon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152
Metformin and cancer: An existing drug for cancer prevention and therapy (Review)
Zi, F., Zi, H., Li, Y., He, J., Shi, Q., & Cai, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7412 · Cited by 152 · cited 1×
“Interestingly, metformin, a drug widely used in the treatment of type 2 diabetes mellitus and polycystic ovary syndrome, seems to possess anti-tumor properties via indirect mTOR protein inhibition [231,232].”
BackgroundPARP inhibitors: A new era of targeted therapy
Tangutoori, S., Baldwin, P., & Sridhar, S. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.01.015 · Cited by 152 · cited 1×
“PARP also plays a role in cell proliferation, differentiation, and transformation [139,140].”
BackgroundImmune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
Konstantinidou, M., Zarganes‐Tzitzikas, T., Magiera‐Mularz, K., Holak, T. A., & Dömling, A. S. S. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201710407 · Cited by 147 · cited 2×
“Pembrolizumab (Keytruda), another anti-PD-1 antibody approved by the FDA across a range of cancers [203] is tested with APG-115 in patients with advanced solid tumors and unresectable or metastatic melanomas (NCT03611868).”
BackgroundSelf-citationActinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells
Kleeff, J., Kornmann, M., Sawhney, H., & Korc, M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000501)86:3<399::aid-ijc15>3.0.co;2-g · Cited by 145
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
Barbieri, E., Mehta, P., Chen, Z., Zhang, L., Slack, A., Berg, S., & Shohet, J. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0305 · Cited by 144 · cited 1×
“nutlin-3a liposarcoma, RMS, neuroblastoma, osteosarcoma [42,43]”
The missing Zinc: p53 misfolding and cancer
Loh, S. N. (2010) · Metallomics · doi:10.1039/c003915b · Cited by 133 · cited 1×
“The p53 protein binds to DNA by a domain which is stabilized by a zinc atom, which is why its role is so important in forming p53 DNA-binding domain complex [219].”
BackgroundAcquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Bosschieter, J., Nieuwenhuijzen, J. A., van Ginkel, T., Vis, A. N., Lissenberg-Witte, B. I., Newling, D. W. W., Beckers, G. M. A., & van Moorselaar, R. J. A. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.038 · Cited by 131
Villalonga-Planells, R., Coll-Mulet, L., Martínez-Soler, F., Castaño, E., Acebes, J.-J., Giménez-Bonafé, P., Gil, J., & Tortosa, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018588 · Cited by 129 · cited 1×
“Furthermore, nutlin-3a strengthened the radiation response of glioma cell lines harboring wild-type p53 [53].”
BackgroundNiu, X., Wang, G., Wang, Y., Caldwell, J. T., Edwards, H., Xie, C., Taub, J. W., Li, C., Lin, H., & Ge, Y. (2014) · Leukemia · doi:10.1038/leu.2014.72 · Cited by 126
Kojima, K., Shimanuki, M., Shikami, M., Samudio, I. J., Ruvolo, V. R., Corn, P. G., Hanaoka, N., Konopleva, M. Y., Andreeff, M., & Nakakuma, H. (2008) · Leukemia · doi:10.1038/leu.2008.158 · Cited by 124 · cited 1×
“A different research group has found that PI3K/mTOR inhibitor PI103 causes a reduction in p53 level, which has been raised when a combination with nutlin-3 was applied [85].”
BackgroundRask, K., Th�rn, M., Pont�n, F., Kraaz, W., Sundfeldt, K., Hedin, L., & Enerb�ck, S. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000501)86:3<337::aid-ijc6>3.0.co;2-3 · Cited by 117
Proteasome Inhibition in the Treatment of Cancer
Richardson, P. G., Mitsiades, C., Hideshima, T., & Anderson, K. C. (2005) · Cell Cycle · doi:10.4161/cc.4.2.1414 · Cited by 113 · cited 2×
“Therefore, inhibition of proteasome activity is a promising anti-cancer strategy (briefly reviewed in [210,211]).”
BackgroundCombined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Laroche-Clary, A., Chaire, V., Algeo, M.-P., Derieppe, M.-A., Loarer, F. L., & Italiano, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0482-3 · Cited by 111 · cited 3×
“Simultaneous treatment caused a significant increase in apoptosis in the in vitro studies, which was later confirmed by tumor volume regression in the in vivo experiments with a mice xenograft model of dedifferentiated liposarcoma [88].”
BackgroundInfluentialYan, L., Rosen, N. X., & Arteaga, C. L. (2011) · 癌症:英文版 · doi:10.5732/cjc.010.10553 · Cited by 104
Lehmann, C., Friess, T., Birzele, F., Kiialainen, A., & Dangl, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0280-3 · Cited by 104 · cited 3×
“venetoclax idasanutlin AML, neuroblastoma AML, neuroblastoma xenograft mouse models AML patients, Phase 1b/2 [64,65] NCT02670044”
BackgroundInfluentialWiedmann, R. M., von Schwarzenberg, K., Palamidessi, A., Schreiner, L., Kubisch, R., Liebl, J., Schempp, C., Trauner, D., Vereb, G., Zahler, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1772 · Cited by 102
Richardson, P. G. G., Eng, C., Kolesar, J., Hideshima, T., & Anderson, K. C. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.681376 · Cited by 101 · cited 1×
“Perifosine, a synthetic alkyl-phospholipid, which is known to inhibit Akt, has been combined with nutlin-3 and showed increased antileukemic activity [86,191].”
BackgroundMiyachi, M., Kakazu, N., Yagyu, S., Katsumi, Y., Tsubai-Shimizu, S., Kikuchi, K., Tsuchiya, K., Iehara, T., & Hosoi, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2955 · Cited by 100 · cited 6×
“M is ce ll an eo us A nt iC an ce r A ge nt s A nt ib io ti cs actinomycin D nutlin-3 RMS [101]”
BackgroundInfluentialKojima, K., Konopleva, M., Samudio, I. J., Schober, W. D., Bornmann, W., & Andreeff, M. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3520 · Cited by 100
Estrada‐Ortiz, N., Neochoritis, C. G., & Dömling, A. (2016) · ChemMedChem · doi:10.1002/cmdc.201500487 · Cited by 97 · cited 1×
“In general, these formulas are designed using the three-finger pharmacophore model in which three substituents are selected to mimic natural interaction between p53 and HDM2 proteins based on Phe19, Trp23 and Leu27 amino acids of the p53 side chain (Figure 2) [111,112].”
MethodTP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Jung, J., Lee, J. S., Dickson, M. A., Schwartz, G. K., Le Cesne, A., Varga, A., Bahleda, R., Wagner, A. J., Choy, E., de Jonge, M. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12609 · Cited by 95
Protein kinase C in cancer: The top five unanswered questions
Cooke, M., Magimaidas, A., Casado‐Medrano, V., & Kazanietz, M. G. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22617 · Cited by 95 · cited 1×
“Another class of protein kinases extensively studied in the context of cancer is the family of Protein Kinases C (PKC), composed of at least twelve members [194,195].”
BackgroundLiu, X. F., Xiang, L., Zhou, Q., Carralot, J., Prunotto, M., Niederfellner, G. J., & Pastan, I. H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611481113 · Cited by 90
McCormack, E., Haaland, I., Venås, G., Forthun, R. B., Huseby, S., Gausdal, G., Knappskog, S., Micklem, D., Lorens, J. B., Bruserud, Ø., et al. (2011) · Leukemia · doi:10.1038/leu.2011.315 · Cited by 88 · cited 2×
“VPA nutlin-3 AML AML xenograft mouse models [100]”
BackgroundSignificance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells
Flandrin‐Gresta, P., Guyotat, D., Duval, A., Cornillon, J., Tavernier, E., Nadal, N., & Campos, L. (2008) · Cell Stress and Chaperones · doi:10.1007/s12192-008-0035-3 · Cited by 87 · cited 3×
“Heat Shock Protein Inhibitor Heat shock proteins (HSPs) are responsible for the proper folding of synthesized proteins or refolding under denaturating conditions [224].”
BackgroundDynamics of targeted cancer therapy
Božić, I., Allen, B., & Nowak, M. A. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.04.006 · Cited by 86 · cited 1×
“These pathways regulate, among other processes, survival, growth, and proliferation [173].”
Backgroundp63/p73 in the control of cell cycle and cell death
Allocati, N., Ilio, C. D., & Laurenzi, V. D. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.01.023 · Cited by 86 · cited 2×
“This p53-independent mechanism might be med ated by other proteins from the p53 family, such as p63 and p73 [181].”
BackgroundRadiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
Cao, C., Shinohara, E. T., Subhawong, T. K., Geng, L., Woon Kim, K., Albert, J. M., Hallahan, D. E., & Lu, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0356 · Cited by 85 · cited 1×
“In another study, nutlin-3 radiosensitized lung cancer cells with wild-type p53, resulting in cell cycle arrest and apoptosis after the combined treatment [137].”
BackgroundA distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85 · cited 1×
“Additionally, a recent study performed with the use of 113 p53wt cell lines showed that 70 of them are naturally resistant to such a treatment [16].”
BackgroundArnhold, V., Schmelz, K., Proba, J., Winkler, A., Wünschel, J., Toedling, J., Deubzer, H. E., Künkele, A., Eggert, A., Schulte, J. H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23409 · Cited by 85 · cited 1×
“The most potent representatives are APG-115 developed by Ascentage Pharma Group (Suzhou, China) [120] and DS-3032b by Daiichi-Sankyo (Tokyo, Japan) [121].”
BackgroundTabe, Y., Sebasigari, D., Jin, L., Rudelius, M., Davies-Hill, T., Miyake, K., Miida, T., Pittaluga, S., & Raffeld, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0399 · Cited by 83 · cited 2×
“Bortezomib has exhibited anti-cancer activity against mantle cell lymphoma, and the addition of nutlin-3 has resulted in synergistic cytotoxicity regardless of mutational p53 status in cancer cell lines [97].”
BackgroundSaha, M. N., Jiang, H., Jayakar, J., Reece, D., Branch, D. R., & Chang, H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.11.11882 · Cited by 82 · cited 2×
“Additionally, p53-induced repression of the anti-apoptotic protein, survivin was observed [96].”
BackgroundState of the art in anti-cancer mAbs
Chiavenna, S. M., Jaworski, J. P., & Vendrell, A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-016-0311-y · Cited by 82 · cited 1×
“Targeted therapies based on monoclonal antibodies that block numerous oncogenic pathways are widely studied [198,199].”
BackgroundChen, L., Rousseau, R. F., Middleton, S. A., Nichols, G. L., Newell, D. R., Lunec, J., & Tweddle, D. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3504 · Cited by 81 · cited 7×
“Topotecan and doxorubicin, which are topoisomerase inhibitors, synergize with idasanutlin in p53wt neuroblastoma cells [34].”
InfluentialFuret, P., Masuya, K., Kallen, J., Stachyra-Valat, T., Ruetz, S., Guagnano, V., Holzer, P., Mah, R., Stutz, S., Vaupel, A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.010 · Cited by 80 · cited 1×
“Further development of the dihydroisoquinoline scaffold resulted in a new class of compounds with the pyrazolo-pyrrolidinone core, represented by the HDM-201 (siremadlin) compound [124].”
BackgroundV-ATPase Inhibition Regulates Anoikis Resistance and Metastasis of Cancer Cells
Schempp, C. M., von Schwarzenberg, K., Schreiner, L., Kubisch, R., Müller, R., Wagner, E., & Vollmar, A. M. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0484 · Cited by 80
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 79 · cited 1×
“Since the discovery of the first potent small-molecular inhibitors of HDM2-p53 interactions, numerous chemical scaffolds have been published and tested [31,109].”
BackgroundZhang, X. P., Liu, F., & Wang, W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.134650 · Cited by 78 · cited 4×
“Moreover, even though oridonin did not increase the level of p53, HDM2, and Puma in the combined strategy nutlin-3 completely abolished the viability of cancer cells.”
BackgroundInfluentialMDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Ohnstad, H. O., Paulsen, E. B., Noordhuis, P., Berg, M., Lothe, R. A., Vassilev, L. T., & Myklebost, O. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-211 · Cited by 77
Verstovšek, S., Golemović, M., Kantarjian, H. M., Manshouri, T., Estrov, Z. E., Manley, P. W., Sun, T., Arlinghaus, R. B., Alland, L., Dugan, M. H., et al. (2005) · Cancer · doi:10.1002/cncr.21299 · Cited by 77 · cited 1×
“Nilotinib (AMN107, Tasigna), a Bcr-Abl tyrosine kinase antagonist, inhibits the expression of anti-apoptotic BCL-2 proteins [153,154].”
BackgroundWeng, H., Huang, H., Dong, B., Zhao, P., Zhou, H., & Qu, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1748 · Cited by 76 · cited 1×
“Oridonin, a bioactive constituent of a Chinese medicinal herb, which previously had been known as a modulator of BCL-2 levels in melanoma and leukemia, is a potent agent in combination therapy [155,156].”
BackgroundFuret, P., Chêne, P., Pover, A. D., Stachyra, T., Lisztwan, J. H., Kallen, J. A., & Masuya, K. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.083 · Cited by 74 · cited 1×
“The design is based on the new, ‘central valine’ concept, which reflects the idea of placing a planar-aromatic ring near the Val93 residue [122].”
MethodOoi, M. G. M., Hayden, P. J., Kotoula, V., McMillin, D. W., Charalambous, E., Daskalaki, E., Raje, N. S., Munshi, N. C., Chauhan, D., Hideshima, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1071 · Cited by 74 · cited 3×
“Furthermore, the scientists have postulated that, as a consequence of nutlin-3 action, molecular pathways associated with poorer responsiveness to bortezomib may be counteracted [95].”
BackgroundInfluentialDeben, C., Wouters, A., de Beeck, K. O., van Den Bossche, J., Jacobs, J., Zwaenepoel, K., Peeters, M., Van Meerbeeck, J., Lardon, F., Rolfo, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4433 · Cited by 73 · cited 1×
“In nasopharyngeal carcinoma cells (NPC) the same therapy showed that nutlin-3 made NPC cells more sensitive to cisplatin-related cytotoxicity; another study indicates that non-small cell lung cancer cell lines are more prone to apoptosis after the combination therapy administration [39,40,42].”
BackgroundArya, A. K., El-Fert, A., Devling, T., Eccles, R. M., Aslam, M. A., Rubbi, C. P., Vlatković, N., Fenwick, J., Lloyd, B. H., Sibson, D. R., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605739 · Cited by 73 · cited 1×
“Nutlin-3 induces senescence and radiosensitivity of laryngeal carcinoma cells (LSCC) retaining wild-type p53 [52].”
BackgroundProlonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
Skalniak, L., Kocik, J., Polak, J., Skalniak, A., Rak, M., Wolnicka-Glubisz, A., & Holak, T. (2018) · Cancers · doi:10.3390/cancers10110396 · Cited by 73
Self-citationWIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma
Richter, M. C., Dayaram, T., Gilmartin, A. G., Ganji, G., Pemmasani, S. K., Key, H. V. D., Shohet, J. M., Donehower, L. A., & Kumar, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115635 · Cited by 73 · cited 1×
“Overexpression of this protein has been observed in human cancers, particularly of breast and ovarian origin [142].”
BackgroundCanner, J. A., Sobo, M., Ball, S., Hutzen, B., DeAngelis, S., Willis, W., Studebaker, A. W., Ding, K., Wang, S., Yang, D., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605199 · Cited by 72 · cited 4×
“MI-319 in combination with cisplatin i r . i t it - i t t r s t t s stai a age response.”
BackgroundInfluentialHuang, B., Deo, D., Xia, M., & Vassilev, L. T. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0144 · Cited by 72 · cited 1×
“In many additional p53wt cell lines HDM2 antagonists induce cell cycle arrest, which is more like reversible quiescence rather than irreversible senescence [6].”
BackgroundThe Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 72 · cited 1×
“It has been shown that the level of XIAP is regulated by HDM2 [159].”
BackgroundYi, H., Yan, X., Luo, Q., Yuan, L., Li, B., Pan, W., Zhang, L., Chen, H., Wang, J., Zhang, Y., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0765-8 · Cited by 71 · cited 1×
“The combination of APG-115 with radiation resulted in cell cycle arrest and apoptosis of these cells [138].”
BackgroundZhang, W., Konopleva, M., Burks, J. K., Dywer, K. C., Schober, W. D., Yang, J.-Y., McQueen, T. J., Hung, M.-C., & Andreeff, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-0878 · Cited by 70
Drakos, E., Singh, R. R., Rassidakis, G. Z., Schlette, E. J., Li, J., Claret, F. X., Ford, R. J., Vega, F., & Medeiros, L. J. (2011) · Leukemia · doi:10.1038/leu.2011.28 · Cited by 70
Cheok, C. F., Dey, A., & Lane, D. P. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0161 · Cited by 69 · cited 3×
“nutlin-3a melanoma, breast, colon adenocarci-noma, liver carcinoma [90]”
BackgroundGenome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
Stolte, B., Iniguez, A. B., Dharia, N. V., Robichaud, A. L., Conway, A. S., Morgan, A. M., Alexe, G., Schauer, N. J., Liu, X., Bird, G. H., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171066 · Cited by 68 · cited 5×
“Su st ai ni ng GSK2830371 ATSP-7041 Ewing sarcoma [57]”
BackgroundInfluentialFeedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 System
Hat, B., Kochańczyk, M., Bogdał, M. N., & Lipniacki, T. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004787 · Cited by 68 · cited 2×
“Since the transition from p53ARRESTER to p53KILLER requires the accumulation of HIPK2 kinase (homeodomain-interacting protein kinase 2) in response to severe DNA damage [25] and normally occurs after several cycles of the induction of p53ARRESTER protein [22,26,27], it is not easily achieved by a rough p53 release evo…”
BackgroundCarter, B. Z., Mak, D. H., Schober, W. D., Koller, E., Pinilla, C., Vassilev, L. T., Reed, J. C., & Andreeff, M. (2010) · Blood · doi:10.1182/blood-2009-03-212563 · Cited by 67 · cited 3×
“M im et ic s 1396-11 nutlin-3a AML [66] ABT-10”
BackgroundInfluentialAzmi, A. S., Aboukameel, A., Banerjee, S., Wang, Z., Mohammad, M., Wu, J., Wang, S., Yang, D., Philip, P. A., Sarkar, F. H., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.015 · Cited by 67 · cited 3×
“Furthermore, this phenomenon was reversible by a zinc chelator, TPEN (N,N,N′,N′-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine), which clearly suggests a crucial zinc role in this process [38].”
BackgroundActinomycin D inhibits cell proliferations and promotes apoptosis in osteosarcoma cells.
Lu, D., Wang, Y., Li, C., Wei, G., Chen, R., Dong, D.-M., & Yao, M. (2015) · PubMed · Cited by 66
The RAF-MEK-ERK Pathway: Targeting ERK to Overcome Obstacles of Effective Cancer Therapy
Yu, Z., Ye, S., Hu, G., Lv, M., Tu, Z., Zhou, K., & Li, Q. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.143 · Cited by 65
Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64
Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
París, R., Henry, R. E., Stephens, S. J., McBryde, M., & Espinosa, J. M. (2008) · Cell Cycle · doi:10.4161/cc.6420 · Cited by 63 · cited 1×
“First, it soon became clear that HDM2 antagonists induce apoptosis only in a limited subset of p53wt cells [4,5].”
BackgroundMonoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Cuesta-Mateos, C., Alcaraz-Serna, A., Somovilla-Crespo, B., & Muñoz-Calleja, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01936 · Cited by 63 · cited 1×
“mAbs are the most successful therapeutic agents, for both, the solid tumors [200], and leukemias or lymphomas [201].”
BackgroundZanjirband, M., Edmondson, R. J., & Lunec, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9499 · Cited by 63 · cited 3×
“p53 activation, enhanced apoptosis and cell cycle arrest [34,37].”
BackgroundRichmond, J., Carol, H., Evans, K., High, L., Mendomo, A., Robbins, A., Meyer, C., Venn, N. C., Marschalek, R., Henderson, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2300 · Cited by 62 · cited 11×
“The co-crystal structures with HDM2 (for example see PDB ID: 4HG7, 4JRG) showed that the two cis-oriented phenyl rings occupy Leu27 and Trp23 pockets, whereas the alkoxy group (isopropoxy in case of nutlin-3a and ethoxy in RG7112) fits into Phe19 pocket.”
ResultInfluentialCould valproic acid be an effective anticancer agent? The evidence so far
Brodie, S. A., & Brandes, J. C. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.940329 · Cited by 62 · cited 1×
“Valproic acid (VPA) inhibits the action of class I HDACs [214].”
Backgroundde Weger, V. A., de Jonge, M., Langenberg, M. H. G., Schellens, J. H. M., Lolkema, M., Varga, A., Demers, B., Thomas, K., Hsu, K., Tuffal, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0355-8 · Cited by 62
Wu, C.-E., Esfandiari, A., Ho, Y.-H., Wang, N., Mahdi, A. K., Aptullahoglu, E., Lovat, P., & Lunec, J. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.433 · Cited by 61 · cited 3×
“the phosphorylated state of key proteins engaged in DNA damage response [15].”
BackgroundInfluentialKasper, E., Angot, É., Colasse, É., Nicol, L., Sabourin, J., Adriouch, S., Lacoume, Y., Charbonnier, C., Raad, S., Frébourg, T., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.011 · Cited by 60 · cited 1×
“Mitotic inhibitors, especially spindle poisons, are claimed to have a relatively low genotoxicity score [230].”
BackgroundWIP1 phosphatase as pharmacological target in cancer therapy
Pecháčková, S., Burdová, K., & Macůrek, L. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1536-2 · Cited by 60 · cited 1×
“Wip1 is a negative regulator of multiple DNA damage response proteins, such as p53, CHK2 (checkpoint kinase 2), histone H2AX, and ATM (Ataxia telangiectasia mutated) (Figure 3) [141].”
BackgroundObinutuzumab: a new class of anti-CD20 monoclonal antibody
Gagez, A.-L., & Cartron, G. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000107 · Cited by 59 · cited 1×
“Pre-clinical data suggests that obinutuzumab is more efficient than rituximab in depleting B cells [205] and has a better toxicological profile, while rituximab therapy causes increased resistance generation [206,207].”
BackgroundCarita, G., Frisch-Dit-Leitz, E., Dahmani, A., Raymondie, C., Cassoux, N., Piperno-Neumann, S., Némati, F., Laurent, C., de Koning, L., Halilovic, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9552 · Cited by 58 · cited 3×
“to decrease the tumor volume in patient-derived xenograft mouse models [91].”
BackgroundInfluentialMolina, J. R., & Adjei, A. A. (2006) · Journal of Thoracic Oncology · doi:10.1097/01243894-200601000-00004 · Cited by 57
Receptor Tyrosine Kinases: Role in Cancer Progression
Sangwan, V., & Park, M. (2006) · Current Oncology · doi:10.3390/curroncol13050019 · Cited by 56
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
Weisberg, E., Halilovic, E., Cooke, V. G., Nonami, A., Ren, T., Sanda, T., Simkin, I., Yuan, J., Antonakos, B., Barys, L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0429 · Cited by 56 · cited 7×
“midostaurin CGM097 AML AML xenograft mouse models [44,73]”
BackgroundInfluentialBose, P., Gandhi, V. V., & Keating, M. J. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1239717 · Cited by 56 · cited 2×
“Ibrutinib is a novel inhibitor of Bruton’s tyrosine kinase present on B-cells [180].”
BackgroundSaiki, A. Y., Caenepeel, S., Yu, D., Lofgren, J. A., Osgood, T., Robertson, R., Canon, J., Su, C., Jones, A., Zhao, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1918 · Cited by 55 · cited 13×
“Pr o- Su rv iv al Si gn al in g Pa th w ay s Ta rg et in g R as /R af /M EK /M A PK In hi bi to rs pimasertib SAR405838 - - different tumor types, Phase 1 NCT01985191[81] trametinib AMG-232 different human cancer cell lines colorectal cancer xenograft mousemodels AML, Phase 1b melanoma, Phase 1 [78,79] NCT02016729 NCT…”
BackgroundInfluentialHoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2506 · Cited by 52 · cited 2×
“In hi bi to rs ABT-263 SAR405838 ALL and AML ALL and AML xenograft mouse models [10]”
BackgroundZauli, G., Celeghini, C., Melloni, E., Voltan, R., Ongari, M., Tiribelli, M., di Iasio, M. G., Lanza, F., & Secchiero, P. (2012) · Haematologica · doi:10.3324/haematol.2012.062083 · Cited by 51 · cited 4×
“When nutlin-3 was combined with sorafenib, a multi-kinase inhibitor, a synergistic cytotoxic effect was observed in AML cell lines [74].”
BackgroundInfluentialRibas, J., Boix, J., & Meijer, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.04.021 · Cited by 50 · cited 2×
“Roscovitine and nutlin-3 were additionally found to pharmacologically synergize in neuroblastoma [89].”
BackgroundZauli, G., Voltan, R., Bosco, R., Melloni, E., Marmiroli, S., Rigolin, G. M., Cuneo, A., & Secchiero, P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2572 · Cited by 49
Jak, M., van Bochove, G. G. W., Reits, E. A., Kallemeijn, W. W., Tromp, J. M., Umaña, P., Klein, C., van Lier, R. A. W., van Oers, M. H. J., & Eldering, E. (2011) · Blood · doi:10.1182/blood-2011-01-331702 · Cited by 49
Bartel, K., Winzi, M., Ulrich, M. P., Koeberle, A., Menche, D., Werz, O., Müller, R., Guck, J. R., Vollmar, A. M., & von Schwarzenberg, K. (2016) · Oncotarget · doi:10.18632/oncotarget.14339 · Cited by 48
Azmi, A. S., Banerjee, S., Ali, S., Wang, Z., Bao, B., Beck, F. W. J., Maitah, M., Choi, M., Shields, T. F., Philip, P. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.269 · Cited by 48 · cited 2×
“In all these three types of tumors, the improved growth inhibition was observed [54].”
BackgroundPan, Y., Xu, R., Peach, M., Huang, C.-P., Branstetter, D., Novotny, W. F., Herbst, R. S., Eckhardt, S., & Holland, P. M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.456 · Cited by 48
Meijer, A., Kruyt, F. A. E., van der Zee, A. G. J., Hollema, H., Le, P., ten Hoor, K. A., Groothuis, G. M. M., Quax, W. J., de Vries, E. G. E., & de Jong, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.636 · Cited by 47 · cited 4×
“The synergistic interactions of both nutlin-3 and rhTRAIL (dularemin) and nutlin-3 and DR-5-selective TRAIL variant, D269H/E195R [172], have been estimated by the researchers in Groningen [67].”
BackgroundInfluentialZinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics
Kogan, S., & Carpizo, D. R. (2018) · Cancers · doi:10.3390/cancers10060166 · Cited by 47 · cited 2×
“ZMCs are small-molecule metal ion chelators that have the ability to donate zinc to mutant p53 which lacks Zn2+ [221].”
BackgroundCarter, B. Z., Mak, P. Y., Mak, D. H. F., Ruvolo, V. R., Schober, W. D., McQueen, T. J., Cortes, J. E., Kantarjian, H. M., Champlin, R. E., Konopleva, M. Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5890 · Cited by 45 · cited 1×
“, nutlin-3 sensitized the patients’ chronic myeloid leukemia cells to nilotinib treatment, even though the cells were initially resistant to this drug [61].”
BackgroundWang, H. Q., Halilovic, E., Li, X., Liang, J., Cao, Y., Rakiec, D. P., Ruddy, D. A., Jeay, S., Wuerthner, J. U., Timple, N., et al. (2017) · eLife · doi:10.7554/elife.17137 · Cited by 45 · cited 3×
“The authors point out that HDM2 inhibition is especially valuable for the treatment of MYCN-amplified neuroblastoma cell lines, as these cells show remarkable sensitivity to MDM2 antagonists in vitro [69].”
BackgroundInfluentialSeipel, K., Marques, M. A. T., Sidler, C., Mueller, B. U., & Pabst, T. (2018) · Haematologica · doi:10.3324/haematol.2018.191650 · Cited by 45 · cited 9×
“midostaurin CGM097 AML AML xenograft mouse models [44,73]”
BackgroundInfluentialZanjirband, M., Curtin, N., Edmondson, R. J., & Lunec, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19266 · Cited by 44 · cited 3×
“One of the nonclinical studies focused on combining nutlin-3a or idasanutlin with a PARP inhibitor, rucaparib, in ovarian cancer cell lines [59].”
BackgroundInfluentialNutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity
VOON, Y.-L., Ahmad, M., Wong, P., Husaini, R., Ng, W., Leong, C., Lane, D. P., & Khoo, A. S. B. (2015) · Oncology Reports · doi:10.3892/or.2015.4177 · Cited by 44
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
Sriraman, A., Radovanovic, M., Wienken, M., Najafova, Z., Li, Y., & Dobbelstein, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9302 · Cited by 44 · cited 2×
“nutlin-3a osteosarcoma, breast, colon adenocarcinoma [58]”
BackgroundA therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
Skalniak, L., Surmiak, E., & Holak, T. A. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1582645 · Cited by 43 · cited 3×
“work on the optimization of lead molecules [30,31], much effort has been done in the last ten years in the field of the development of combined treatment strategies, that would incorporate HDM2 antagonists into successful anti-cancer treatment regimes.”
BackgroundSelf-citationTonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42
Zhu, N., Gu, L., Li, F., & Zhou, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0179 · Cited by 42
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A., & Dobbelstein, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0968-0 · Cited by 40 · cited 3×
“The authors concluded that employing both therapies simultaneously may, in fact, be counterproductive and result in an unfavorable outcome for patients [87].”
BackgroundInfluentialWu, C., Koay, T. S., Esfandiari, A., Ho, Y.-H., Lovat, P. E., & Lunec, J. (2018) · Cancers · doi:10.3390/cancers11010003 · Cited by 40 · cited 4×
“idasanutlin cutaneous melanoma [82] nutlin-3”
BackgroundInfluentialRucaparib: A Review in Ovarian Cancer
Shirley, M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00629-5 · Cited by 40 · cited 1×
“PARP also plays a role in cell proliferation, differentiation, and transformation [139,140].”
BackgroundJones, R. J., Baladandayuthapani, V., Neelapu, S. S., Fayad, L., Romaguera, J. E., Wang, M. L., Sharma, R., Yang, D., & Orlowski, R. Z. (2011) · Blood · doi:10.1182/blood-2011-03-340323 · Cited by 39 · cited 7×
“The analysis of the co-crystal structures of MI-63 analogs suggests that the oxindole part tightly occupies the Trp23 pocket, the aliphatic neo-pentyl substituent fits into Phe19 pocket, and substituted phenyl fits into the Leu26 pocket (for example see PDB ID: 3LBL).”
MethodInfluentialDiscontinued drugs in 2012: oncology drugs
Williams, R. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.847088 · Cited by 38 · cited 1×
“However, the development of drozitumab has been discontinued in 2010 [208].”
BackgroundHaaland, I., Opsahl, J. A., Berven, F. S., Reikvam, H., Fredly, H., Haugse, R., Thiede, B., McCormack, E., Laín, S., Bruserud, Ø., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-116 · Cited by 38 · cited 2×
“Combination treatment of Hsp90 inhibitor geldanamycin and nutlin-3 showed synergistic effect by inducing apoptosis in AML cell lines and primary AML cells [104].”
BackgroundLaroche, A., Chaire, V., Algeo, M.-P., Karanian, M., Fourneaux, B., & Italiano, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16345 · Cited by 38 · cited 3×
“Idasanutlin and BEZ235, a PI3K and mTOR inhibitor, elicited a strong therapeutic response in well-differentiated/dedifferentiated liposarcomas, which corresponded with consistent induction of apoptosis and p53 level upon the combined treatment [83].”
BackgroundInfluentialTrino, S., Iacobucci, I., Erriquez, D., Laurenzana, I., Luca, L. D., Ferrari, A., di Rorà, A. G. L., Papayannidis, C., Derenzini, E., Simonetti, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7339 · Cited by 37
Muta, Y., Matsuda, M., & Imajo, M. (2019) · Cancers · doi:10.3390/cancers11040513 · Cited by 37
Zajkowicz, A., Gdowicz‐Kłosok, A., Krześniak, M., Ścieglińska, D., & Rusin, M. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.05.005 · Cited by 36 · cited 2×
“In another study with the same combination, the synergic effect on cancer cell lines has been confirmed [102].”
BackgroundGu, Z., Wang, X., Qi, R., Wei, L., Huo, Y., Ma, Y., Shi, L., Chang, Y., Li, G., & Zhou, L. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.12.086 · Cited by 36 · cited 1×
“Oridonin, a bioactive constituent of a Chinese medicinal herb, which previously had been known as a modulator of BCL-2 levels in melanoma and leukemia, is a potent agent in combination therapy [155,156].”
Background
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
Targeting apoptotic pathways for cancer therapy
Tian, X., Srinivasan, P. R., Tajiknia, V., Uruchurtu, A. S. S., Seyhan, A. A., Carneiro, B. A., Cruz, A. D. L., Pinho-Schwermann, M. P., George, A., Zhao, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179570 · Cited by 172
“The first approach uses agents targeting p53-negative regulators to activate WT p53, such as MDM2 inhibitors (69, 70).”
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
Skalniak, L., Kocik, J., Polak, J., Skalniak, A., Rak, M., Wolnicka-Glubisz, A., & Holak, T. (2018) · Cancers · doi:10.3390/cancers10110396 · Cited by 73
Self-citationMDM2: current research status and prospects of tumor treatment
Yao, Y., Zhang, Q., Li, Z., & Zhang, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03356-8 · Cited by 82
“Safe dose intravenous injection of RO6839921 showed good anti-tumor activity in osteosarcoma and AML xenograft models [87].”
Background
Metadata
- Authors
- Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L.
- Affiliations
- Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30–387 Krakow, Poland
- Jagiellonian University (PL)
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-07-19
- Volume
- 11
- Issue
- 7
- Pages
- 1014
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6678622
- OpenAlex
- W2963228228
- Cited by
- 46
- References
- 237
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 11 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 8
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Narodowe Centrum Nauki (UMO-2016/21/D/NZ7/00596)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, MDM2, combination therapy, anticancer activity, apoptosis, TP53 mutation, synergistic effect, cancer therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.